Prosigna: A Tool in the Fight Against Breast Cancer.
The fight against breast cancer has seen significant progress thanks to the incorporation of cutting-edge diagnostic tools. Among them, the Prosigna test stands out as one of the most revolutionary. This article will explore in depth what Prosigna is, how it works, and why it is crucial in personalizing breast cancer treatment. Furthermore, we will analyze scientific studies that support its effectiveness and discuss how this tool can be integrated into cancer treatment in Mexico.
What is Prosigna?
Prosigna is an advanced genomic test designed to assess the risk of breast cancer recurrence. Based on PAM50 technology, Prosigna analyzes the expression of 50 genes in tumor tissue to classify breast cancer into one of four intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, and Basal-like. This classification is essential for personalizing treatment and improving patient outcomes.
How does Prosigna work?
The Prosigna test is performed on tumor tissue obtained during a biopsy or surgery. The process includes several key steps:
- RNA extractionRNA is extracted from tumor tissue.
- Amplification and labelingRNA is amplified and labeled with specific fluorophores.
- Hybridization in a microarrayThe labeled RNA is hybridized into a microarray containing probes for the 50 genes of the PAM50 panel.
- Data analysisGene expression is analyzed using specific algorithms that generate a recurrence risk index (ROR).
Prosigna Benefits
- Treatment personalizationProsigna allows doctors to personalize treatment according to the breast cancer subtype, thus improving treatment effectiveness and reducing unnecessary side effects.
- Accurate risk assessmentThe test provides an accurate assessment of the risk of recurrence, helping patients and doctors to make informed decisions about adjuvant treatment.
- Optimizing the use of chemotherapyProsigna can help identify patients who will benefit from chemotherapy and those who can avoid it, reducing exposure to unnecessary toxic treatments.
Scientific Studies that Support Prosigna
A study published in Clinical Cancer Research The study evaluated Prosigna's ability to predict breast cancer recurrence compared to other available methods. The results showed that Prosigna provides greater accuracy in predicting recurrence risk, especially in patients with early-stage breast cancer. .
Another study in The Lancet Oncology The study analyzed the effectiveness of Prosigna in classifying breast cancer subtypes and its impact on treatment decisions. It concluded that Prosigna not only improves the accuracy of subtype classification but also positively influences treatment selection, optimizing outcomes for patients. .
Integration of Prosigna into Cancer Treatment in Mexico
In Mexico, the integration of advanced technologies like Prosigna into cancer treatment can make a significant difference in the fight against breast cancer. The benefits include better treatment personalization, more accurate assessment of recurrence risk, and optimized use of medical resources.
For oncologists in Mexico, incorporating Prosigna into their clinical practice can mean greater confidence in treatment planning and improved patient outcomes. Furthermore, patients can benefit from more personalized and effective treatments, improving their quality of life and long-term outlook.
Conclusion
Prosigna represents a significant advancement in personalized breast cancer treatment. Its ability to accurately assess recurrence risk and classify cancer into specific subtypes makes it an invaluable tool for oncologists and their patients. By integrating Prosigna into cancer treatment in Mexico, we can improve the quality of care and outcomes for breast cancer patients.
We also invite you to our upcoming webinar on Prosigna, which will take place on August 8th at 8:00 AM Mexico City time. This event will be an opportunity to delve deeper into the use of Prosigna, its benefits, and the scientific evidence that supports it. Don't miss this opportunity to learn from experts in the field and discover how this tool can transform cancer care. Join us! Here's the link. here.
Sources
- Dowsett, M., et al. (2013). Prosigna assay: Predicting risk of recurrence in breast cancer. Clinical Cancer Research. Retrieved from Clinical Cancer Research.
- Parker, J.S., et al. (2009). Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. The Lancet Oncology. Retrieved from The Lancet Oncology.
